TCBP 2.56 TC Biopharm (Holdings) Plc
| Range: | 2.11-1140.0 | Vol Avg: | 245548 | Last Div: | 0 | Changes: | -0.06 |
| Beta: | 0.11 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Feb 11 2022 | Empoloyees: | 41 | ||
| CUSIP: | 87807D103 | CIK: | 0001872812 | ISIN: | US87807D4007 | Country: | GB |
| CEO: | Mr. Bryan Leland Kobel | Website: | https://www.tcbiopharm.com | ||||
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow